单克隆抗体在中度至严重的亚托皮性皮肤炎的II期和III期试验中
Heli A Patel1, Linh Tran2, Ralina Karagenova3
1Center for Dermatological Research, Wake Forest University, Winston-Salem, NC, USA.
Expert opinion on emerging drugs
|October 10, 2024
概括
新型单克隆抗体疗法显示出治疗亚托皮性皮肤炎 (AD) 的巨大潜力,提供了有前途的向治疗方法. 这些先进的治疗方法在减少疾病严重程度,改善患者的治疗结果方面表现出有效性.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 亚托皮炎 (AD) 是一种广泛的慢性炎症性皮肤疾病,影响生活质量.
- 目前对阿尔茨海默病的治疗包括皮质类固醇和免疫调节剂,以及新兴的单克隆抗体疗法.
研究的目的:
- 审查和讨论针对阿托皮性皮肤炎的新型单克隆抗体疗法.
- 分析这些先进治疗方法在治疗AD中的作用和有效性.
主要方法:
- 系统搜索NIH临床试验数据库 (2023年9月至2024年1月) 的二期和三期AD试验.
- 包括基于美国的试验,将新疗法与安慰剂进行比较,使用关键词如"皮炎"和"单克隆抗体".
- 利用公司网站和摘要获取最新的试验结果.
主要成果:
- 单克隆抗体向AD中的特定炎症媒介.
- 第二期和第三期试验显示出强大的治疗潜力,在湿疹区域和严重性指数 (EASI) 得分上显著降低.
结论:
- 单克隆抗体代表了一种有前途的新向性皮肤炎治疗选择.
- 这些疗法有可能改变AD的管理.
关键词:
亚托邦性皮肤炎 (Atopic Dermatitis) 是一种不良的疾病.生物学的生物学.临床试验是指临床试验中的临床试验.免疫调节的免疫调节这是一种单克隆抗体.第二阶段试验的试验.第三阶段试验的试验.更多相关视频
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
241
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
241
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143


